Long term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile

Long term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile - Golimumab in rheumatoid arthritis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36406

Enrollment

200

Registered

2011-02-16

Start date

2011-03-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory rheumatic disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with rheumatoid arthritis in whom golimumab treatment is started. written informed consent.

Exclusion criteria

Exclusion criteria: contraindications against golimumab treatment

Design outcomes

Primary

Measure	Time frame
Efficacy will be determined in comparison to baseline by measuring disease activity, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of side effects. Changes in lipid profile markers during the four years of treatment will be analyzed versus baseline.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results